Related Experiment Videos
Molecular pathogenesis of malignant gliomas
B K Rasheed1, R N Wiltshire, S H Bigner
1Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Current Opinion in Oncology
|May 18, 1999
Summary
De novo and progressive glioblastomas have distinct genetic profiles. Understanding these differences, including CDKN2A deletions and p53 mutations, aids in classifying brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Molecular Pathology
Background:
- Glioblastomas are classified as either de novo or progressive.
- De novo glioblastomas occur in older patients without prior tumors, while progressive glioblastomas arise from lower-grade astrocytomas in younger patients.
Purpose of the Study:
- To investigate the distinct genetic alterations in de novo versus progressive glioblastomas.
- To identify genetic markers differentiating tumor types and origins.
Main Methods:
- Comparative analysis of genetic profiles, including CDKN2A deletions, PTEN alterations, EGFR amplification, and p53 mutations.
- Assessment of Loss of Heterozygosity (LOH) patterns for chromosome 10, 1p, and 19q.
Main Results:
- De novo glioblastomas show higher prevalence of CDKN2A deletions, PTEN alterations, and EGFR amplification.
- Progressive glioblastomas are more frequently associated with p53 mutations.
- Loss of heterozygosity for chromosome 10 is common in both types, suggesting a potential novel tumor suppressor gene.
- Oligodendrogliomas exhibit frequent 1p/19q LOH, linking oligoastrocytomas with 1p/19q LOH to oligodendrogliomas.
Conclusions:
- Distinct genetic landscapes characterize de novo and progressive glioblastomas.
- Genetic profiling is crucial for understanding glioblastoma origins and for potential therapeutic strategies.
- Further research is needed to identify the tumor suppressor gene telomeric to PTEN.